The Latest Breaking News from Guggenheim

Guggenheim has decided to maintain its Buy rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $25.00 to $5.00. Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

Teladoc Health Inc (NYSE: TDOC) is a market leader in digital services, and the breadth of its services is unmatched, according to Guggenheim. The Teladoc Health Analyst: Sandy Draper initiated coverage of Teladoc Health with a Buy rating and $96 price target.

Analysts lowered their price target on Domino's Pizza Inc (NYSE:DPZ) following the company's Q4 results. Citi analyst Sergio Matsumoto lowered the price target to $480 (18% upside) from $540 and kept a Neutral rating on the shares. The analyst cited forecast decreases and market conditions for the reduced price target. Barclays analyst Jeffrey Bernstein lowered…

Gainers KAR Auction Services, Inc. (NYSE: KAR) shares climbed 39.2% to $19.05 after the company agreed to sell its ADESA U.S. physical auction business to Carvana for $2.2 billion. Guggenheim upgraded KAR Auction Services from Sell to Neutral.

Truist analyst Stephanie Moore lowered the price target on IAA Inc (NYSE:IAA) to $50 (an upside of 40.5%) from $75 and maintained a Buy rating on the shares. The analyst mentioned the company reported a Q4 EBITDA miss and offered "mixed" FY22 guidance on EBITDA margin, but the subsequent 22% stock price decline is "overdone." Moore…